**Amendment no. 1**

**NO. BPPI/DRUG/RC-116/2019**

**Dated: 18/10/2019**

**Subject:** - Tender No. BPPI/DRUG/RC-116/2019 dated 04/10/2019 for supply of Drugs to Bureau of Pharma Public Sector Undertakings of India (BPPI).

**Reference:** - Pre-Bid meeting held on 11.10.2019 at 11:00 AM in the premises of BPPI

The following amendment in Tender Document is hereby authorized:

**PART- A**

<table>
<thead>
<tr>
<th>Sl. No.</th>
<th>Tender Clause/Reference</th>
<th>Query/Suggestion</th>
<th>Clarification/ Amendment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Clause 3. (A) &amp; Clause 6 (A)</td>
<td>Bidder has requested to reduce the EMD amount to 50 thousand as against 10 lakhs stating that they are going to participate for only one drug.</td>
<td>Tender provision prevails.</td>
</tr>
<tr>
<td>2</td>
<td>Clause 3 (G)</td>
<td><strong>WHO-GMP (WHO-Good Manufacturing Practice) as per revised Schedule- ‘M’/COPP Certificate of the manufacturing unit issued by the Licensing Authority/ Drugs Control Department.</strong> The WHO-GMP certificate must not be older than one year from the last date of submission of tender. Self-attested copies are to be submitted. <strong>Explanation-</strong> Generally the WHO-GMP Certificate issued for one-year validity. Hence the provision that it should not be older than one year from the last date of submission of tender implies mutatis mutandis that the GMP certificate should remain valid till the last date of submission of tender.</td>
<td>The clause no. Clause 3 (G) is amended as under: - <strong>Valid WHO-GMP (WHO-Good Manufacturing Practice) as per revised Schedule- ‘M’/COPP Certificate of the manufacturing unit issued by the Licensing Authority/ Drugs Control Department.</strong> The WHO-GMP certificate must be valid as on the last date of submission of tender. Self-attested copies are to be submitted in hard copy.</td>
</tr>
<tr>
<td>3</td>
<td>Sl. No. 6 of Annexure I Check List (Whether Uploaded the documents) COVER – A</td>
<td><strong>Copies of WHO-GMP (WHO-Good Manufacturing Practice) as per revised Schedule- ‘M’/COPP Certificate of the manufacturing unit issued by the Licensing Authority/ Drugs Control Department/FDA. The WHO-GMP certificate must not be older than one year from the last date of submission of tender as per Clause 3. G.</strong></td>
<td>Copies of <strong>WHO-GMP (WHO-Good Manufacturing Practice) as per revised Schedule- ‘M’/COPP Certificate of the manufacturing unit issued by the Licensing Authority/ Drugs Control Department/FDA.</strong> The WHO-GMP certificate must be valid as on the last date of submission of tender as per Clause 3. G.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
</tbody>
</table>
| 4 | Sl. No. 14 of Annexure I Checklist and clause 3 (I) | Bidder asked to modify Sl. No. 14 in Annexure I as the turnover is mentioned 50 crores as against 25 Crores in Clause No. 3 (I) | Modified Sl. No. 14 of ANNEXURE – I can be read as under   
Audited Annual Balance sheet and Profit and loss statement showing details of their Annual average turn over not less than 25 (twenty-five) crores for three consecutive financial years as per Clause 3. I.   |
| 5 | Clause 4(G) | Bidder asked clarification above, whether they should submit the declaration regarding the Active API Polymorphic use in formulation with technical bid | Bidder shall submit Declaration on their letter head that they are using Internationally accepted Active polymorphs for quoted drugs, whenever asked by BPPI.   |
| 6 | Note of clause 3, serial no. (iii) and Annexure I (Checklist) | One of the bidders mentioned that they are not clear from tender as which of the document they need to submit in cover A in hard copies. | It is clearly communicated in the pre-bid meeting that all the documents shall reach BPPI Head-office in hard copy as a part of technical bid (Cover A) as per Annexure I checklist. Also note EMD instrument, ANNEXURE II, ANNEXURE IV, ANNEXURE V and ANNEXURE VI required in its original, whereas rest of the document shall be duly attested by authorized signatory/authorized person.   |
| 7 | Clause no. 19 (D), Sr. No, 4 of delivery schedule table | Bidders has requested to amend the supply period against first order from 45 days to 60 days and for subsequent purchase orders from 30 days to 45 days respectively for all drugs except Injectable/Infusion/Vials (Products do not required sterility testing). | Clause no. 19 (D), Sr. No, 4 of delivery schedule table shall be read as: The Delivery Schedule against subsequent P.O. for all drugs except Injectable/Infusion/Vials (Products do not required sterility testing) is here by amended from 30 days to 45 days.   |
| 8 | Clause 3(I) | One of the participants in the pre-bid meeting has requested to relax the condition of annual turnover of Rs. 25 crores to 2 crores. | Tender provision prevails.   |
| 9 | Clause 17 (A) | In the Pre-bid meeting, representative of a MSME firm has requested to relax the provision of deduction of Performance Security Deposit @ 5% from each running bills for MSMEs. | Tender provision prevails.   |
| 10 | Clause no. 15 B and 16 A | M/S Inventia Healthcare Pvt. Ltd. asked clarification about the new provision added in the subject tender | Tender provision prevails.   |
where it is mentioned to offer Purchase preference as against price preference in earlier tenders in case of the bidders submit COPP/USFDA or approval from any other foreign accreditation for quoted product as mentioned

PART B: - (i)

<table>
<thead>
<tr>
<th>Sl. No.</th>
<th>Tender Clause/Reference No.</th>
<th>Drug Code &amp; Drug Specification</th>
<th>Query/Suggestion</th>
<th>Amendment</th>
</tr>
</thead>
</table>
| 1      | Sr. No. 167 of Annexure -XII | Drug code 560, FLUTICASONE PROPIONATE NASAL SPRAY 50 mcg Each spray delivers: Fluticasone Propionate IP 50 mcg Unit size 120 MD | Supplier has requested to Amendment the unit size from 120 MD to 100 MD. | The following amendment in unit size for Drug Code 560 (FLUTICASONE PROPIONATE NASAL SPRAY 50 mcg) is hereby authorized as under: -

UNIT SIZE - 100 MD. |
| 2      | Annexure-XII, (Clause 18 E and F) | | | Annexure -XII, Clause 18 (E) and (F) shall be read as Annexure XII 18 (M) |

(ii) The following drug is hereby stands deleted from BOQ (Cover B), Annexure XII, Annexure XIII and Annexure XIV.

<table>
<thead>
<tr>
<th>S.N.</th>
<th>Drug Code</th>
<th>Generic Name of Drug</th>
<th>Composition/Strength</th>
<th>Unit Size</th>
<th>Pack Size</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>130</td>
<td>Chlorhexidine Gluconate and Cetrimide Solution (1.5% w/v and 3% w/v)</td>
<td>Chlorhexidine Gluconate 1.5% w/v, Cetrimide 3% w/v Solution</td>
<td>100ml Bottle</td>
<td>1 x 100 ml</td>
</tr>
<tr>
<td>2</td>
<td>220</td>
<td>Calcium with Vitamin D3 Tablets IP (500mg+250IU)</td>
<td>Each film-coated tablet contains: 1250mg Calcium Carbonate equivalent to Elemental Calcium IP 500mg Vitamin D3 IP 250IU</td>
<td>10's</td>
<td>10's X 10</td>
</tr>
<tr>
<td>3</td>
<td>524</td>
<td>LIGNOCAINE INJECTION IP 2%</td>
<td>Each ml contains: Lignocaine Hydrochloride IP 21.33 mg Sodium chloride IP 6.0 mg</td>
<td>30 ML VIAL</td>
<td>1's x 10</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| **4** | **621** | **Carbonyl Iron, Zinc and Folic Acid Capsules**  
Each capsule contains:  
Elemental Iron 50 mg  
in the form of Carbonyl Iron)  
Zinc Sulphate Monohydrate 61.8 mg  
equivalent to 22.5 elemental Zinc)  
Folic Acid 0.5 mg | **Methyl Paraben IP 1.0 mg**  
as preservative | **15's**  
10 x 15's |
| **5** | **635** | **Clobetasol Propionate, Neomycin Sulphate, Miconazole Nitrate and Chlorhexidine Gluconate Cream**  
Contains:  
Clobetasol Propionate 0.05% w/w  
Neomycin Sulphate 0.50% w/w  
Miconazole Nitrate 2.00% w/w  
Chlorhexidine Gluconate Solution 0.20% w/w  
Chlorocresol (as preservative) 0.10% w/w  
In a cream base q. s. | **Chlorhexidine Gluconate and Cetrimide Solution (0.3% w/v and 0.6% w/v)** | **Chlorhexidine Gluconate 0.3% w/v + Cetrimide 0.6%w/v** | **200 ml**  
1x 200 ml |
| **6** | **659** | **Chlorhexidine Gluconate and Cetrimide Lotion**  
contains:  
Gamma Benzene Hexachloride 1% w/v  
Cetrimide 0.1% w/v | **Rabeprazole 20mg + Domperidone 10mg Capsule**  
Each hard gelatin capsule contains:  
Rabeprazole sodium Ip (as enteric coated pellets) 20mg  
Domperidone Ip (as immediate release pellets) 10mg | **Betamethasone Valerate & Salicylic Acid (0.05% w/w + 3.0% w/w) Ointment**  
Contains:  
Betamethasone Valerate IP equivalent to betamethasone 0.05% w/w  
Salicylic Acid IP 3.0%w/w  
in a greasy base | **20gm Tube**  
1's x 20 |

**PART-C:**

The following Amendment in the key dates of Tender schedule shall be referred as below:

(a) Last date of online submission of the tender in the CPP portal: - 11/11/2019 (MONDAY) Till 17.00 Hours  
(b) Last date of submission of original documents (Cover A): - 15/11/2019 (FRIDAY) at 13.00 Hours  
(c) Opening of the technical bid: - 15/11/2019 (FRIDAY) at 16.00 Hours
The bidders are requested to quote their rate in BOQ considering above amendment/modification/Deletion of drugs in tender document and specification, unit size, pack size in Annexure VII Annexure VIII and BOQ and Amendment in Annexure XII, Annexure XIII and Annexure XIV.

**All other contents of tender document remain unaltered.**

Yours faithfully,

Sd/-

(Anurag Dwivedi)
GM (Procurement)
For & on behalf of BPPI
Ph: 011-49431811